New cardiometabolic program further builds upon
the existing Amwell ecosystem of digital health plan offerings to
improve continuous care for plan members
Amwell® (NYSE: AMWL), a leader in digital healthcare
enablement, today announced the expansion of its digital clinical
programs to include a cardiometabolic program, enabling health
plans and clinicians to seamlessly connect members living with
common chronic diseases, such as diabetes and high blood pressure,
to Dario’s highly personalized digital therapeutic solution on the
Amwell platform.
In partnership with personalized global digital therapeutic
leader DarioHealth (Nasdaq: DRIO), the new cardiometabolic program
builds upon the comprehensive Amwell portfolio of care solutions
and network of affiliated clinicians, designed to address member
needs both in and outside the provider office. Together, the Amwell
digital care delivery platform, Amwell’s affiliated clinicians and
Dario’s clinically proven cardiometabolic digital therapeutic
solution will drive better health outcomes for members through a
continuously connected care experience.
"Member care and engagement are top-of-mind for health plans,
especially as consumers demand more digital tools and effective,
value-driven care,” says Dr. Ido Schoenberg, chairman and co-CEO of
Amwell. “By bringing solutions like Dario into our ecosystem of
care programs, Amwell empowers health plans and their clinicians to
create a more cohesive, integrated, and comprehensive digital
journey for their members. It’s an approach that ultimately drives
better outcomes and more modernized engagement. This new capability
further expands the scope of our single, highly scalable platform
powered by Converge™. It adds yet another important component in
delivering our clients ‘one stop shop’ digital care enablement
solution, addressing their most important and diversified needs
today while being future ready.”
Cardiometabolic conditions such as diabetes and high blood
pressure are some of the most pervasive and costly medical
conditions in the U.S., with more than one-third of Americans
living with metabolic-related health condition1, over 37 million
living with diabetes and an additional 96 million being
pre-diabetic2.
Members receiving care via clinicians practicing on the Amwell
platform can be referred seamlessly to a Dario program, minimizing
roadblocks to care. The Dario solution addresses diabetes, high
blood pressure and weight management needs with a holistic and
highly individualized hybrid care experience. It combines connected
devices, like glucometers, with intelligent data-driven digital
experiences and personalized one-on-one health coaching.
“We are thrilled to partner with Amwell to build a more
connected healthcare experience for members living with
cardiometabolic heath needs,” said Rick Anderson, president of
Dario. “Dario’s highly personalized digital solutions are designed
to complement care from a professional with a proven ability to
drive sustainable behavior change and improve health outcomes.
Integration with Amwell’s market-leading platform will create the
cohesive experience that members want and help deliver better
outcomes for payers.”
To learn more about the Amwell program, click here.
About Amwell
Amwell is a leading digital care delivery enablement platform in
the United States and globally, connecting and enabling providers,
insurers, patients, and innovators to deliver greater access to
more affordable, higher quality care. Amwell believes that digital
care delivery will transform healthcare. The Company offers a
single, comprehensive platform to support all digital health needs
from urgent to acute and post-acute care, as well as chronic care
management and healthy living. With over a decade of experience,
Amwell powers the digital care of more than 55 health plans, which
collectively represent more than 90 million covered lives, and many
of the nation’s largest health systems, representing over 2,000
hospitals, have access to Amwell solutions. For more information,
please visit https://business.amwell.com/.
©2023 American Well Corporation. All rights reserved. Amwell®,
SilverCloud®, Conversa®, ConvergeTM, CarepointTM and the Amwell
Logo are registered trademarks or trademarks of American Well
Corporation. All other trademarks are the property of their
respective owners.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital
therapeutics (DTx) company, revolutionizing how people with chronic
conditions manage their health through a user-centric,
multi-chronic condition platform. Our platform and suite of
solutions deliver personalized and dynamic interventions driven by
data analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral health.
Our user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about DarioHealth and its digital
health solutions, or for more information, visit
http://dariohealth.com.
Forward-Looking Statements
This press release contains forward-looking statements about us
and our industry that involve substantial risks and uncertainties
and are based on our beliefs and assumptions and on information
currently available to us. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations, financial
condition, business strategy and plans and objectives of management
for future operations, are forward-looking statements. In some
cases, you can identify forward-looking statements because they
contain words such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” or “would,” or the negative of these
words or other similar terms or expressions.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Forward-looking statements
represent our beliefs and assumptions only as of the date of this
release. These statements, and related risks, uncertainties,
factors and assumptions, include, but are not limited to: weak
growth and increased volatility in the telehealth market; inability
to adapt to rapid technological changes; increased competition from
existing and potential new participants in the healthcare industry;
changes in healthcare laws, regulations or trends and our ability
to operate in the heavily regulated healthcare industry; our
ability to comply with federal and state privacy regulations; the
significant liability that could result from a cybersecurity
breach; and other factors described under ‘Risk Factors’ in our
most recent form 10-K filed with the SEC. These risks are not
exhaustive. Except as required by law, we assume no obligation to
update these forward-looking statements, or to update the reasons
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future. Further information on factors that could
cause actual results to differ materially from the results
anticipated by our forward-looking statements is included in the
reports we have filed or will file with the Securities and Exchange
Commission. These filings, when available, are available on the
investor relations section of our website at investors.amwell.com
and on the SEC’s website at www.sec.gov.
1
https://www.healthline.com/health-news/more-than-one-third-of-americans-have-dangerous-metabolic-syndrome
2 https://www.cdc.gov/chronicdisease/about/costs/index.htm
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230322005180/en/
press@amwell.com
American Well (NYSE:AMWL)
Historical Stock Chart
Von Mai 2023 bis Jun 2023
American Well (NYSE:AMWL)
Historical Stock Chart
Von Jun 2022 bis Jun 2023
